NEW YORK (GenomeWeb News) – LABS and Ambry Genetics today announced a deal for the provision of testing services in reproductive health.
The deal, which the two firms said will result in services being available to a wider client base, will make Ambry the preferred provider of genetic carrier screening for LABS. Under the terms of the deal, LABS' customers will be able to access AmbryScreen, a genetic screen for identifying carriers of severe and common childhood diseases affecting pan-ethnic populations, the companies said in a joint statement.
"This partnership brings two premier laboratories together to offer new donor and patient screening options combined with an elite level of service that is unparalleled in the reproductive health industry," Elizabeth Hearty, CEO of LABS, said in the statement. "Ambry also brings to the table strong innovation and cutting-edge technologies within the genetic diagnostic market and that will effectively serve our clients."
Financial and other terms of the deal were not disclosed.
Ambry, based in Aliso Viejo, Calif., is a CLIA-certified specialty laboratory focused on genetic testing and diagnostic services. LABS is a transplant medicine reference laboratory headquartered in Centennial, Colo.